Asthma is a chronic inflammatory disease of the airways that causes recurrent episodes of wheeze, breathlessness, chest tightness, and cough. Symptoms can vary over time and are often triggered by allergens, infections, exercise, or irritants.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.
Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07612384 |
Effects of Abdominal Binder on Dysnea, Control Pause and Quality of Life in Asthmatic Patients |
COMPLETED | NA |
| NCT07611955 |
A Study of Acupuncture for Treating Asthma |
NOT_YET_RECRUITING | NA |
| NCT07609134 |
The Development of the Walsh Asthma Self-management Programme and Feasibility of Implementation in Adults With Asthma in Primary Care |
RECRUITING | NA |
| NCT07598292 |
Predicting Dynamic Inspiratory Muscle Strength in COPD and Asthma Patients |
COMPLETED | |
| NCT07589439 |
Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma |
RECRUITING | PHASE2 |
| NCT07574294 |
Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps |
COMPLETED | |
| NCT07567690 |
Real-world Immunogenicity of Anti-IL5/5a Antibody |
ACTIVE_NOT_RECRUITING | |
| NCT07556159 |
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice |
RECRUITING | |
| NCT07548827 |
GINA-P and ACT-P Scores for Assessing Asthma Control |
NOT_YET_RECRUITING | |
| NCT07546981 |
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists |
NOT_YET_RECRUITING | PHASE3 |
